Stoffels Sets Out Strategy To Save Galapagos
Focus On Phase I/II Licensing Rather Than Late-Stage Prospects
Pharma veteran Paul Stoffels, the new CEO of Galapagos, is not thinking about using the Belgian biotech’s cash pile to buy Phase III drugs but is open to licensing deals with US firms who have drugs approved at home and are looking for a European partner.
